Urinary system disorder
MONDO:0002118A disease involving the renal system.
Also known as: disease of renal system, disease or disorder of renal system, disease, urinary tract, disease, urologic, disease, urological, diseases, urinary tract, diseases, urologic, diseases, urological
4758 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1811 trials in this tab.
-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 23:00 UTC
-
Custom-Made cancer vaccine targets leftover disease after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
-
Cell therapy combo aims to boost kidney cancer treatment
Disease control Recruiting nowThis study tests whether adding an experimental cell therapy called IBR854 to the standard drug pazopanib works better than pazopanib alone for advanced kidney cancer. About 30 adults with untreated advanced clear cell renal cell carcinoma will take part. The goal is to see if th…
Phase: PHASE2 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New pill aims to wipe out rare urinary tract cancer without surgery
Disease control Recruiting nowThis study tests a new drug called dabogratinib in 230 adults with a rare, low-grade cancer in the upper part of the urinary tract. The goal is to see if the drug can make the cancer disappear completely within 6 months. Participants take the drug by mouth and are monitored for s…
Phase: PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New radiation approach before surgery for rare adrenal cancer
Disease control Recruiting nowThis early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New stem cell transplant trial offers hope for rare blood diseases
Disease control Recruiting nowThis study tests a stem cell transplant using blood stem cells from a half-matched family donor (haploidentical) for people with severe aplastic anemia, related MDS, or PNH. Participants receive chemotherapy and a single radiation dose before the transplant, plus a drug to preven…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for kidney cancer: triple-drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests three different drug combinations in 120 people with advanced kidney cancer that has spread. The goal is to see which combination works best to shrink tumors. Participants will receive either a new two-drug or three-drug combination, or a standard two-drug therap…
Phase: PHASE2 • Sponsor: Brian Rini • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug aims to outperform chemo in tough bladder cancer
Disease control Recruiting nowThis phase 3 trial tests whether the experimental drug sacituzumab tirumotecan helps people with advanced bladder cancer live longer than standard chemotherapy. About 590 participants whose cancer worsened after prior treatments will receive either the new drug or one of several …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug cocktail aims to stop kidney cancer recurrence in High-Risk patients
Disease control Recruiting nowThis study tests whether adding tivozanib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone to keep kidney cancer from returning after surgery. About 1040 adults with high-risk clear cell renal cell carcinoma will take part. The goal is to see if t…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for advanced bladder cancer patients who have run out of options
Disease control Recruiting nowThis study is for people with advanced bladder cancer that has gotten worse after standard treatment. It tests a new drug combination (datopotamab deruxtecan plus chemotherapy) against another chemotherapy combo. The goal is to see if the new combo can shrink tumors or slow the c…
Phase: PHASE2, PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New stem cell method aims to cut transplant risks
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for people with severe aplastic anemia or other bone marrow failure diseases. Doctors give a smaller number of donor white blood cells along with the stem cells to try to reduce serious side effects. Up to 120 patients aged 4…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug AWT020 takes on advanced solid tumors
Disease control Recruiting nowThis phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo may help bladder cancer patients keep their bladder
Disease control Recruiting nowThis study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to stop kidney damage in membranous nephropathy
Disease control Recruiting nowThis study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a simple sugar powder help save kidneys? new trial underway for FSGS
Disease control Recruiting nowThis phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…
Phase: PHASE2 • Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug aims to slow kidney failure in rare genetic disease
Disease control Recruiting nowThis study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Bladder cancer combo trial: could adding chemo to BCG keep tumors away?
Disease control Recruiting nowThis phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG therapy can better prevent high-grade bladder cancer from coming back. About 330 people with recurrent non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemcitabin…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Blood test may tell who needs extra immunotherapy after bladder cancer surgery
Disease control Recruiting nowThis large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for young lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Engineered immune cells take on kidney cancer in first human test
Disease control Recruiting nowThis early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, w…
Phase: PHASE1 • Sponsor: Hrain Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo aims to spare bladders in cancer patients
Disease control Recruiting nowThis phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how ma…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug duo aims to rescue PNH patients failing standard care
Disease control Recruiting nowThis study tests two experimental drugs, pozelimab and cemdisiran, together in 35 adults with paroxysmal nocturnal hemoglobinuria (PNH) whose red blood cell destruction is not well-controlled by current C5 inhibitors. The goal is to see if the combination can lower hemolysis (bre…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Could a diabetes drug shield kidneys from autoimmune attack?
Disease control Recruiting nowThis trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Real-World test: can a targeted drug keep PNH in check for years?
Disease control Recruiting nowThis study follows about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking pegcetacoplan (Aspaveli/Empaveli) as part of their routine care. Researchers will track blood markers, symptoms, and side effects for up to 3 years to see how well the drug works out…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a Two-Drug punch revive immunotherapy for tough bladder cancers?
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug could help kidney transplant patients avoid rejection
Disease control Recruiting nowThis study tests if a new drug called siplizumab can safely prevent kidney transplant rejection better than the current standard treatment. About 120 adults receiving a kidney transplant will be split into three groups: two groups get different doses of siplizumab, and one gets t…
Phase: PHASE2 • Sponsor: Nefro Avillion Clinical Development, LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a low protein diet keep kidneys working longer?
Disease control Recruiting nowThis study tests whether a carefully controlled low protein diet (about 0.6 grams of protein per kilogram of body weight each day) can help people with advanced chronic kidney disease delay the need for dialysis or a kidney transplant. The study enrolls adults with stage 4-5 or f…
Phase: NA • Sponsor: Centre Hospitalier le Mans • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Needle vs. scalpel: which dialysis access works best?
Disease control Recruiting nowThis study compares two methods for creating an arteriovenous fistula (AVF) in people with end-stage kidney disease who need dialysis. The newer endovascular method uses a needle through the skin, while the traditional surgical method requires an incision. Researchers will enroll…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Gene therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThis phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a bone marrow infusion help kidney transplant patients ditch lifelong pills?
Disease control Recruiting nowThis phase 1 trial tests whether giving a bone marrow infusion along with a deceased donor kidney transplant can help the body accept the new kidney without needing lifelong anti-rejection drugs. The study enrolls adults with end-stage kidney disease who are already listed for a …
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a stem cell infusion free kidney transplant patients from lifelong drugs?
Disease control Recruiting nowThis study tests whether a special treatment before a kidney transplant can help the body accept the new organ without needing lifelong anti-rejection drugs. Participants receive radiation and immune-suppressing drugs, followed by an infusion of donor stem cells and the patient's…
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to calm kidney attack by antibodies
Disease control Recruiting nowThis study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which i…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with tough infections: experimental antibiotic combo tested
Disease control Recruiting nowThis study tests a new IV antibiotic (aztreonam-avibactam) in hospitalized children aged 9 months to 18 years with serious gram-negative bacterial infections. About 48 participants will receive either the new drug or the best available standard treatment. The goal is to see how t…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults will receive either …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a 4-Week radiation course be as good as 5 weeks for prostate cancer?
Disease control Recruiting nowThis study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …
Phase: NA • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immunotherapy boost before surgery shows promise for rare urinary tract cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for Hard-to-Treat cancers enters first human tests
Disease control Recruiting nowThis early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…
Phase: PHASE1 • Sponsor: Degron Therapeutics Co. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug SLV-154 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …
Phase: PHASE1 • Sponsor: Solve Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Tiny radioactive spheres aim to destroy kidney tumors without surgery
Disease control Recruiting nowThis study tests the safety and effectiveness of a treatment called radioembolization for people with early stage kidney cancer. Tiny glass spheres containing radioactive yttrium-90 are injected into the artery feeding the tumor to destroy it from inside. The trial will enroll 25…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug option for Hard-to-Treat cancers with FGFR3 mutations
Disease control AVAILABLEThis expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …
Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New shortcut for blood pressure treatment?
Disease control Recruiting nowThis study tests a faster version of a procedure called renal denervation, which uses energy to calm overactive nerves in the kidneys to lower blood pressure. About 130 adults with uncontrolled high blood pressure will receive the quicker procedure. The goal is to see if it works…
Phase: NA • Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New mRNA injection aims to tame autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kids with rare blood disorders: benralizumab trial launches
Disease control Recruiting nowThis Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive in…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New bladder cancer therapy shows promise in early trial
Disease control Recruiting nowThis phase 2 study is testing a new treatment called TARA-002 for people with a type of high-grade bladder cancer that hasn't spread into the muscle. The treatment is given directly into the bladder through a catheter once a week for 6 weeks. The study will include about 131 adul…
Phase: PHASE2 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug INCA036873 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Lupus drug trial aims for remission without daily pills
Disease control Recruiting nowThis study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Zapping stubborn cancer spots may extend life of current drug therapy
Disease control Recruiting nowThis study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Gene therapy breakthrough targets kidney disease in High-Risk patients
Disease control Recruiting nowThis study tests a new gene therapy, PS-002, for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The therapy aims to control the disease in people who are at high risk of getting worse despite current treatments. Participants receive a single dose a…
Phase: PHASE1, PHASE2 • Sponsor: Purespring Therapeutics Limited • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Food as medicine: new study tests groceries and coaching to fight high blood pressure
Disease control Recruiting nowThis study tests whether giving people access to healthy foods, personalized dietitian coaching, and a home blood pressure monitor can help Black and Hispanic adults with high blood pressure (and often diabetes) get their numbers down. About 100 participants will be randomly assi…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common vitamin restore immunotherapy power after antibiotics?
Disease control Recruiting nowThis study looks at whether taking vitamin B3 (a common dietary supplement) can stop antibiotics from weakening the immune system's ability to fight bladder cancer. The trial includes people with a certain type of bladder cancer who have recently taken antibiotics. They will rece…
Phase: PHASE1 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could an allergy drug protect kidneys in type 1 diabetes?
Disease control Recruiting nowThis study tests whether montelukast, a common allergy medication, can lower protein levels in urine and improve kidney and blood vessel function in people with type 1 diabetes who have early signs of kidney disease. Inflammation is thought to play a role in diabetic kidney damag…
Phase: PHASE4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New dialysis solution may delay need for full treatment in kidney patients
Disease control Recruiting nowThis trial investigates whether using icodextrin, a special dialysis solution, can help people on peritoneal dialysis (a type of home dialysis for kidney failure) stay on a lower-dose regimen for longer. Participants are randomly assigned to receive either icodextrin or a standar…
Phase: PHASE4 • Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug danicopan under Real-World review for rare blood disorder
Disease control Recruiting nowThis study tracks 8 Korean patients with paroxysmal nocturnal hemoglobinuria (PNH) who are taking Danicopan alongside standard C5 inhibitors like eculizumab or ravulizumab. The goal is to monitor safety and check if the drug works as expected in everyday medical practice. It is a…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Weight loss program could open door to kidney transplants for obese patients
Disease control Recruiting nowThis study tests a virtual weight management program for 60 adults with obesity and advanced kidney disease who want to lose weight to become eligible for a kidney transplant. Participants either join the program (which includes coaching and a weight-loss medication called semagl…
Phase: PHASE4 • Sponsor: Western University, Canada • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug MK-4884 tested for safety in advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody MTX-439 enters first human trial for diabetic kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called MTX-439, an antibody that blocks a protein linked to kidney scarring. It will be given to healthy volunteers and people with diabetic kidney disease to check for safety and how the body processes it. The study is small (88 participan…
Phase: PHASE1 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could fight bladder cancer without surgery
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called TYRA-300 in 90 adults with a low-grade, intermediate-risk bladder cancer that has not invaded muscle. The cancer must have a specific genetic change (FGFR3 alteration). Participants take a daily tablet for up to 2 years. The main goal …
Phase: PHASE2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a common bile acid pill shield kidneys during cancer surgery?
Disease control Recruiting nowThis trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take …
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New bladder cancer drug TARA-002 faces chemotherapy in major trial
Disease control Recruiting nowThis phase 3 trial tests whether a new drug, TARA-002, works better than standard chemotherapy for a type of early-stage bladder cancer. About 284 adults who have not received BCG therapy will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladd…
Phase: PHASE3 • Sponsor: Protara Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for kidney patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug, povetacicept, against a standard treatment (calcineurin inhibitor) in 176 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the new drug can put the disease into remission more safely a…
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could help dialysis patients control dangerous phosphate levels
Disease control Recruiting nowThis study tests a new drug called AP306 in 168 adults on maintenance hemodialysis who have high phosphate levels (hyperphosphatemia). Participants take one of several fixed doses of AP306 or a placebo daily for 8 weeks. The main goal is to see if AP306 safely lowers blood phosph…
Phase: PHASE2 • Sponsor: R1 Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill aims to protect kidneys in diabetes patients
Disease control Recruiting nowThis study tests whether a new drug called R3R01 can reduce the amount of protein leaking into the urine in adults with type 2 diabetes and kidney disease. About 60 participants will take either R3R01 or a placebo for 3 months. Researchers will measure urine protein, kidney funct…
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Diabetes drug semaglutide tested in dialysis patients for safety
Disease control Recruiting nowThis study tests whether semaglutide, a diabetes drug, is safe and tolerable for people with type 2 diabetes who are on dialysis. About 100 participants will either receive weekly semaglutide injections or standard care for 26 weeks. The goal is to see if patients can stick with …
Phase: PHASE4 • Sponsor: Unity Health Toronto • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to calm immune attacks on kidneys
Disease control Recruiting nowThis Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…
Phase: PHASE2 • Sponsor: Vera Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a Two-Drug combo protect kidneys and hearts?
Disease control Recruiting nowThis phase 3 trial is testing whether adding baxdrostat to the standard drug dapagliflozin can better protect the kidneys and heart in 5000 adults with chronic kidney disease and high blood pressure. Participants will receive either the combination or dapagliflozin alone. The stu…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Immune cell therapy takes on kidney disease
Disease control Recruiting nowThis early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for kids with kidney disease: finerenone safety trial underway
Disease control Recruiting nowThis study tests the long-term safety of finerenone, a drug that helps control a key system involved in kidney damage, in children aged 1 to 18 with chronic kidney disease and proteinuria. All 100 participants will take finerenone alongside their usual ACE inhibitor or ARB medica…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to fight advanced kidney cancer
Disease control Recruiting nowThis study tests whether a combination of two oral drugs, belzutifan and zanzalintinib, works better than the current standard drug cabozantinib for people with advanced kidney cancer that has come back after prior treatment. About 904 participants will be randomly assigned to on…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug pegcetacoplan tested in teens with rare blood disorder
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in 12 to 17-year-olds with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug aims to control the disease by blocking part of the immune system. The trial will check safety, how the…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to spare bladders in cancer patients
Disease control Recruiting nowThis phase II trial is testing whether giving the immunotherapy drug pembrolizumab along with radiation therapy after chemotherapy can help patients with muscle invasive bladder cancer avoid bladder removal surgery. About 111 participants who responded well to initial chemotherap…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New implant aims to quiet bladder urgency for years
Disease control Recruiting nowThis study is checking how well the Altaviva™ device works over five years for people with sudden, strong urges to urinate (urge incontinence). The device sends mild electrical pulses to a nerve in the ankle to calm bladder signals. Researchers will track 256 adults to see if at …
Phase: NA • Sponsor: MedtronicNeuro • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for bladder cancer: experimental drug joins standard combo
Disease control Recruiting nowThis study tests whether adding an experimental drug (MK-3120) to the standard treatment (enfortumab vedotin plus pembrolizumab) is safe and effective for people with advanced bladder cancer that has spread. About 55 participants will receive the new combination. Researchers will…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill combo aims to fight advanced kidney cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a vitamin-like pill shield your heart during surgery? new trial aims to find out.
Disease control Recruiting nowThis phase 2 trial is testing whether a supplement called nicotinamide mononucleotide (NMN) can protect the heart and kidneys of people undergoing coronary artery bypass surgery. Researchers will give NMN or a placebo to 90 adults at higher risk of complications. The main goal is…
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to protect kidneys in diabetes
Disease control Recruiting nowThis Phase 2 trial tests two experimental drugs, ALN-ANG3 and evinacumab, in 270 people with diabetic kidney disease. The drugs block a protein called ANGPTL3 to lower blood fats. Researchers will measure changes in urine protein and kidney function over time to see if the drugs …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo pill aims to cut heart deaths in patients with failing kidneys
Disease control Recruiting nowThis Phase 3 trial is testing whether a combination of two drugs, balcinrenone and dapagliflozin, works better than dapagliflozin alone to prevent heart failure events and cardiovascular death. About 4,800 adults with heart failure and moderate-to-severe kidney impairment who rec…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for advanced kidney cancer: experimental drug pumitamig enters human trials
Disease control Recruiting nowThis study tests a new drug called pumitamig, alone or combined with ipilimumab or cabozantinib, in 254 people with advanced kidney cancer that cannot be removed by surgery. The goal is to see if the drug is safe and can shrink tumors. Participants must have a confirmed diagnosis…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug fabhalta under Real-World watch in korea for rare blood and kidney diseases
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to s…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Donor cells take on Drug-Resistant viruses in new trial
Disease control Recruiting nowThis early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain c…
Phase: PHASE1, PHASE2 • Sponsor: LucasBio • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New care plan aims to keep kidney patients out of the hospital
Disease control Recruiting nowThis study tests whether a personalized care plan at hospital discharge helps people who survived acute kidney injury recover better. Depending on their risk level, patients get education, a primary care visit, or specialist monitoring. The goal is to see if this approach increas…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Creatine and exercise during dialysis: a new hope for kidney patients?
Disease control Recruiting nowThis study tests whether taking creatine supplements and doing light exercise during dialysis sessions can help people with advanced kidney disease maintain muscle strength and body health. About 48 adults on dialysis will take either creatine or a placebo daily for 8 weeks, whil…
Phase: PHASE1, PHASE2 • Sponsor: Pedro Julian Flores Moreno • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells take on bladder cancer in early trial
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy called 4SCAR-T cells in 20 people with advanced bladder cancer that has spread and no longer responds to standard treatments. The cells are genetically modified to recognize and attack cancer cells. The study aims to see if…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New gel could outperform standard therapy for kidney disease
Disease control Recruiting nowThis Phase 3 trial is testing a new gel called SNP-ACTH (1-39) against the standard drug rituximab in 148 adults with primary membranous nephropathy, a rare kidney condition. The goal is to see if the gel can better reduce protein in the urine and protect kidney function over 24 …
Phase: PHASE3 • Sponsor: Cerium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could diabetes pills boost cancer immunotherapy?
Disease control Recruiting nowThis phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Engineered immune cells aim to tame lupus without daily pills
Disease control Recruiting nowThis phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a diabetes pill protect kids' kidneys? new trial launches
Disease control Recruiting nowThis study tests whether empagliflozin, a medicine already used for diabetes, can help children aged 2 to 17 with chronic kidney disease. About 120 kids will take either the drug or a placebo for 6 months, then everyone gets the drug for a year. Researchers will check kidney func…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can 'Supercharged' donor cells beat viruses that drugs Can't?
Disease control Recruiting nowThis study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pump could make dialysis access easier for kidney patients
Disease control Recruiting nowThis study tests a device called the Amplifi Vein Dilation System, which is a temporary blood pump used before creating a dialysis access point (fistula) in the arm. The goal is to see if it helps widen small veins so the fistula works better for dialysis. About 160 adults with e…
Phase: NA • Sponsor: Amplifi Vascular, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New scaffold aims to stop leakage after prostate surgery
Disease control Recruiting nowThis study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …
Phase: PHASE3 • Sponsor: Levee Medical, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New dialysis gadget aims to clean blood better and boost life quality
Disease control Recruiting nowThis study tests a special cartridge (pHA130) added to regular dialysis to remove toxins that standard dialysis misses. One hundred adults with kidney failure on maintenance dialysis will be split into two groups: one gets the new cartridge once a week plus standard dialysis twic…
Phase: NA • Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tame rare kidney diseases
Disease control Recruiting nowThis Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to fight kidney cancer when immunotherapy fails
Disease control Recruiting nowThis study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with …
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo aims to wipe out rare bladder cancer before surgery
Disease control Recruiting nowThis Phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) before bladder removal surgery can completely eliminate the cancer in people with a rare, aggressive form of bladder cancer called small cell neuroe…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo aims to outsmart resistant bladder cancer
Disease control Recruiting nowThis phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New kidney drug shows promise in reducing protein leakage
Disease control Recruiting nowThis study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy vs chemo: new hope for bladder cancer patients?
Disease control Recruiting nowThis phase II trial compares two treatments for high-grade T1 bladder cancer that hasn't spread. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy (cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C) plus radiation.…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cells tailored to attack lung cancer show promise in early trial
Disease control Recruiting nowThis trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug zigakibart aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tu…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug aims to shield kidneys in sepsis patients
Disease control Recruiting nowThis study tests an experimental drug called AZD4144 in 124 adults with sepsis who have also developed acute kidney injury. Participants receive either the drug or a placebo daily by IV while in the hospital. The main goal is to see if the drug helps maintain kidney function bett…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Two-Drug combo aims to shrink upper tract bladder cancer before surgery
Disease control Recruiting nowThis trial tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before surgery can improve outcomes for people with upper tract urothelial cancer (a type of bladder cancer in the kidney or ureter). Participants receive the drugs intravenously, then undergo surgery …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New trial: could lymph node removal boost survival in kidney cancer?
Disease control Recruiting nowThis trial is testing whether adding a template lymph node dissection (removing nearby lymph nodes) to the standard surgery for high-risk upper tract urothelial cancer helps patients live longer without the cancer returning. About 150 participants will be randomly assigned to get…
Phase: NA • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a single infusion of modified immune cells tame lupus kidney flares?
Disease control Recruiting nowThis study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …
Phase: PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug BHV-1400 tested for kidney disease
Disease control Recruiting nowThis early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.
Phase: PHASE1 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for bladder cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to shield heart and kidneys from major events
Disease control Recruiting nowThis study tests a daily pill called orforglipron to see if it can prevent major heart problems (like heart attacks or strokes) and slow kidney disease in people who already have heart or kidney disease. About 7,140 adults will take either the drug or a placebo for up to 5 years.…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare cancers: drug combo shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receiv…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to stop bleeding in kidney stone surgery
Disease control Recruiting nowThis study tests whether using a hemostatic agent (a substance that stops bleeding) during kidney stone surgery can reduce blood loss compared to standard care. About 92 adults with kidney stones will be randomly assigned to receive either a hemostatic agent or no agent during th…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to protect kidneys and heart in 11,000-Patient trial
Disease control Recruiting nowThis study tests whether adding BI 690517 (Vicadrostat) to empagliflozin can slow kidney disease and prevent heart failure hospitalizations or cardiovascular death in people with chronic kidney disease. About 11,000 adults with or without type 2 diabetes will take either BI 69051…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MRNA vaccine technology takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New device zaps kidney and liver nerves to tame high blood pressure
Disease control Recruiting nowThis study tests a device that uses radiofrequency energy to disrupt nerve signals in the kidney and liver arteries, aiming to lower blood pressure in people with uncontrolled hypertension. About 175 adults aged 18-80 with high blood pressure despite medication will be enrolled. …
Phase: NA • Sponsor: Medtronic Vascular • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can antibiotic wash and suction stop Post-Surgery infections?
Disease control Recruiting nowThis study tests whether using an antibiotic (gentamicin) in the irrigation fluid and a special suction tube during kidney stone surgery can lower the chance of fever, inflammation, or sepsis afterward. About 180 adults having this surgery will be randomly assigned to receive one…
Phase: NA • Sponsor: Hitit University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can spreading out radiation beat a single dose for brain tumors?
Disease control Recruiting nowThis Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radiation boost may tame untreatable kidney cancer
Disease control Recruiting nowThis phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat cervical cancer
Disease control Recruiting nowThis trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 trial tests whether adding belimumab to standard rituximab treatment helps more people with primary membranous nephropathy achieve remission. The study enrolls 58 adults with confirmed disease. Belimumab targets new immune cells, while rituximab depletes existing one…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a more extensive surgery keep kidney cancer from coming back?
Disease control Recruiting nowThis study compares two surgical approaches for high-risk kidney cancer: a standard limited lymph node removal versus a more thorough 'template' dissection. Researchers want to see if the more extensive surgery helps prevent cancer from returning and improves survival. About 220 …
Phase: NA • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for chronic UTI sufferers: extended antibiotic combo trial launches
Disease control Recruiting nowThis phase II trial tests whether a 12-week course of higher-dose antibiotics combined with a urinary antiseptic (methenamine hippurate) can better control chronic UTI than standard low-dose antibiotics or antiseptic alone. About 192 adults with daily UTI symptoms for at least 3 …
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Supercharged immune cells take on Drug-Resistant infections
Disease control Recruiting nowThis trial investigates whether specially grown immune cells, called pathogen-specific cytotoxic T lymphocytes (CTLs), can safely and effectively treat stubborn infections like EBV, CMV, and adenovirus in people with weakened immune systems, such as stem cell or organ transplant …
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
AI boosts kidney drug dosing: hope for membranous nephropathy patients
Disease control Recruiting nowThis study tests whether artificial intelligence can help doctors personalize rituximab doses for people with membranous nephropathy, an autoimmune kidney disease. About 120 adults with active disease will receive either standard rituximab or AI-guided dosing to keep drug levels …
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Common antibiotic could tame rare calcium disorder
Disease control Recruiting nowThis study tests whether the antibiotic rifampin can safely lower high calcium levels in the blood and urine of people with a rare genetic mutation in the CYP24A1 gene. The condition can cause kidney stones and other problems. Sixty participants aged 6 months to 65 years will tak…
Phase: PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Single-Port robot could make pediatric surgery less invasive
Disease control Recruiting nowThis trial tests whether a new robotic system that uses only one small incision (single port) can safely perform common abdominal surgeries in children. The study includes children aged 1 to 17 who need procedures like pyeloplasty or reflux treatment. The goal is to see if the si…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New kidney drug could help kids with protein leak
Disease control Recruiting nowThis study tests whether adding finerenone to standard blood pressure medicines can reduce protein in the urine of children with chronic kidney disease. About 219 children aged 6 months to under 18 years will take either finerenone or a placebo for 6 months. The main goal is to s…
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-phase trial is testing a new type of immune cell therapy called CLEAR CAR-T (ET-970) in 30 people with advanced clear cell kidney cancer that has not responded to at least two prior treatments. The therapy uses donor immune cells engineered to target a protein called C…
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Gene-Based bladder cancer treatment shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…
Phase: PHASE1, PHASE2 • Sponsor: enGene, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a pill replace needles for anemic kids with kidney disease?
Disease control Recruiting nowThis phase 3 trial tests roxadustat, an oral medication, for treating anemia in children and teenagers with chronic kidney disease. About 100 participants will take the drug three times a week for up to a year. The goal is to see if it can safely raise hemoglobin levels and offer…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to control rare blood disease Long-Term
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of two experimental drugs, pozelimab and cemdisiran, taken together for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 202 participants who completed a prior study will continue treatment to see…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lupus patients: drug trial targets kidney damage
Disease control Recruiting nowThis study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney cancer patients may get a drug holiday thanks to new scan technique
Disease control Recruiting nowThis study tests whether people with advanced kidney cancer can safely pause their medication after one year of treatment. Doctors will use a special PET scan that targets CD70 to decide who qualifies for a treatment break. The goal is to see if patients can stop drugs without th…
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control Recruiting nowThis study tests whether the drug avacopan can help children aged 6 to 18 with a rare autoimmune disease called ANCA-associated vasculitis, which causes inflammation of blood vessels. About 20 participants will receive avacopan alongside standard treatments like rituximab or cycl…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?
Disease control Recruiting nowThis study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. …
Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New adjustable implant aims to stop leakage in women
Disease control Recruiting nowThis trial tests a device called Adjustable Continence Therapy (ACT) for women with stress urinary incontinence caused by a weak urethral sphincter. The implant has two balloons placed near the bladder neck that can be adjusted after surgery to improve control. The study will enr…
Phase: NA • Sponsor: Uromedica • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to help kidney patients fight acid and stay strong
Disease control Recruiting nowThis study tests a drug called veverimer in 150 adults with moderate-to-severe chronic kidney disease (CKD) and a condition called metabolic acidosis, where acid builds up in the blood. The goal is to see if the drug can raise blood bicarbonate levels and improve physical functio…
Phase: PHASE3 • Sponsor: Renibus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gene therapy combo could offer bladder cancer patients an alternative to surgery
Disease control Recruiting nowThis phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…
Phase: PHASE3 • Sponsor: Ferring Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to kickstart transplanted kidneys faster
Disease control Recruiting nowThis phase 3 trial tests whether ravulizumab, given intravenously, can reduce the severity of delayed graft function (DGF) in adults at high risk after kidney transplant. DGF is when the new kidney is slow to start working, often requiring dialysis. The study will compare ravuliz…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for PNH patients with stubborn anemia
Disease control Recruiting nowThis study tests an experimental drug called ALN-CFB in people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cells despite standard treatment. The goal is to see if adding ALN-CFB is safe and can improve anemia. About 24 participants will receive eit…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slow kidney damage in rare disease
Disease control Recruiting nowThis study tests an experimental drug called ALXN1920 in 30 adults with primary membranous nephropathy, a rare kidney disease that can lead to kidney failure. Participants are at high risk for their disease getting worse. The study compares the drug to a placebo to see if it redu…
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Kidney transplant trial tests which drug better prevents rejection
Disease control Recruiting nowThis phase 3 trial compares two induction therapies—rabbit anti-thymocyte globulin (rATG) and basiliximab—in 244 sensitized kidney transplant recipients who do not have pre-existing donor-specific antibodies. The goal is to see which drug better prevents biopsy-proven acute rejec…
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Bladder wash could cut infections and hospital visits for catheter users
Disease control Recruiting nowThis study tests whether a bladder wash with a low-dose antiseptic (chlorhexidine) during routine catheter changes can reduce urinary tract infections and unplanned healthcare visits. Seventy adults with a long-term suprapubic catheter and a history of UTIs will receive the wash …
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on seven tough cancers
Disease control Recruiting nowThis phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breathing in chemo: new hope for lung metastases?
Disease control Recruiting nowThis early-phase study tests a chemotherapy drug (gemcitabine) given as a mist to breathe in. It is for people whose solid tumors have spread to the lungs and who have no standard treatment options. The main goal is to find the safest dose and watch for side effects. Up to 44 par…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody cocktail takes on tough lupus kidney disease
Disease control Recruiting nowThis early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug aims to protect kidneys in PMN patients
Disease control Recruiting nowThis Phase 3 study tests a new drug called felzartamab in 180 people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. Felzartamab is a lab-made antibody designed to stop that attack. The study compares felzartamab to …
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to protect kidney transplants from early failure
Disease control Recruiting nowThis study tests whether adding terlipressin to standard care helps maintain stable blood pressure during kidney transplant surgery. Researchers will compare two groups of 150 adults: one receiving terlipressin plus dobutamine, the other dobutamine alone. The main goal is to see …
Phase: NA • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplant breakthrough? albumin may shield kidneys
Disease control Recruiting nowThis study tests whether giving extra albumin (a protein in the blood) after a liver transplant can prevent acute kidney injury. About 400 adult liver transplant recipients will be split into two groups: one gets albumin to keep levels above 30 g/L for five days, the other only g…
Phase: PHASE4 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat kidney tumors
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The dr…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stem cell therapy aims to restore kidney function in early trial
Disease control Recruiting nowThis study tests a new treatment called AdiaVita, made from umbilical cord stem cells, for adults with chronic kidney disease. About 100 people aged 18 to 80 with moderate kidney problems will receive monthly infusions and a daily skin spray for three months. The goal is to see i…
Phase: PHASE1 • Sponsor: Adia Med of Winter Park LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Starch-Based drug clean toxins from dialysis Patients' blood?
Disease control Recruiting nowThis trial tests whether a drug called coated aldehyde oxystarch (Xiqing) can reduce protein-bound uremic toxins in adults with end-stage renal disease who are on dialysis. Participants take the drug three times daily for three months. Researchers measure toxin levels in the bloo…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug LOXO-435 targets Hard-to-Treat bladder cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising new therapy targets rare, aggressive cancers
Disease control Recruiting nowThis study tests whether the drug ubamatamab, alone or with cemiplimab, can help control rare cancers like renal medullary carcinoma and epithelioid sarcoma. About 40 adults with advanced or metastatic disease will receive the treatment to check safety and effectiveness. The goal…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tackle Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…
Phase: PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Daily pill aims to improve bladder function in children with spinal conditions
Disease control Recruiting nowThis study tests a daily pill called vibegron to see if it safely improves bladder control in children aged 2 to 18 with neurogenic detrusor overactivity (NDO), a condition where the bladder contracts too often due to nerve damage. Participants must already use a catheter to empt…
Phase: PHASE2, PHASE3 • Sponsor: Urovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Needle-Sized device could replace surgery for dialysis access
Disease control Recruiting nowThis study tests a new device that creates a connection between an artery and a vein using a small needle puncture instead of open surgery. The goal is to provide a reliable access point for dialysis in people with kidney failure. About 126 adults will be enrolled and followed fo…
Phase: NA • Sponsor: Venova Medical • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare cancers: experimental drug ADCT-701 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to control bladder cancer without surgery
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug enfortumab vedotin with radiation therapy can help control locally advanced bladder cancer. About 41 adults with urothelial carcinoma of the bladder will receive the drug by IV along with radiation. The main goal is to …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Rechargeable implant offers hope for bladder control – but does it last?
Disease control Recruiting nowThis study is following 55 adults who have an implanted device that stimulates nerves to control overactive bladder. Researchers want to see if the device safely improves quality of life over the long term. Participants must have already tried other treatments without success.
Phase: NA • Sponsor: Axonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare vasculitis: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease by reducing inflammation. Participants will receive …
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New bladder cancer combo shows promise in Pre-Surgery trial
Disease control Recruiting nowThis study tests whether a new combination of drugs (enfortumab vedotin plus toripalimab) works better than standard chemotherapy before bladder cancer surgery. About 58 adults with high-risk muscle-invasive bladder cancer will be randomly assigned to one of the two treatments fo…
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a diabetes drug protect kidneys in polycystic disease? new trial aims to find out
Disease control Recruiting nowThis phase 3 trial tests whether the drug dapagliflozin can slow the loss of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD), a common genetic cause of kidney failure. The study will enroll 420 people aged 18 to 60 with rapid disease progressio…
Phase: PHASE3 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy could protect kidneys and hearts without High-Dose statins
Disease control Recruiting nowThis study compares two cholesterol-lowering strategies in about 1,950 adults with chronic kidney disease and heart or blood vessel disease. One group gets a moderate-dose statin plus ezetimibe, the other gets a high-dose statin alone. The goal is to see if the combo is just as g…
Phase: NA • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer gel shows promise for rare urinary tract tumors
Disease control Recruiting nowThis study tests a new gel-like drug, UGN-104, placed directly into the upper urinary tract to treat low-grade cancer. About 70 adults with small tumors will receive the treatment to see if it can completely eliminate visible cancer. The goal is to control the disease and avoid m…
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AB821 enters first human tests for advanced melanoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Bubble blast: new device aims to shatter kidney stones without surgery
Disease control Recruiting nowThis study tests a new device called the Enhanced Lithotripsy System (ELS) that uses low-pressure ultrasound to activate tiny bubbles in the urine, breaking kidney or ureter stones into small pieces that can pass naturally. The trial will enroll 101 adults with a single stone in …
Phase: NA • Sponsor: Avvio Medical • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to slow kidney failure in IgA nephropathy patients
Disease control Recruiting nowThis phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets genetic form of polycystic kidney disease
Disease control Recruiting nowThis study tests an experimental drug called VX-407 in 24 adults with autosomal dominant polycystic kidney disease (ADPKD) who have specific changes in the PKD1 gene. The goal is to see if the drug can slow kidney growth and is safe. Participants take VX-407 tablets by mouth and …
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New siRNA drug ADX-038 enters human trials for PNH anemia
Disease control Recruiting nowThis study tests a new drug called ADX-038 in healthy volunteers and people with PNH who still have low red blood cells despite treatment. The goal is to check safety and how the drug works in the body. It is an early-stage trial with 50 participants.
Phase: PHASE1, PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New program aims to boost kidney treatment in diabetes patients
Disease control Recruiting nowThis study is testing an education program for people with type 2 diabetes who also have chronic kidney disease. The program provides patients with information about their kidney health and suggests medications that could slow kidney damage. Researchers will see if this approach …
Phase: NA • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug YH32364 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New immune drug AZD6750 targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Banked immune cells show promise against Life-Threatening viruses in transplant patients
Disease control Recruiting nowThis early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Walking and education may protect kidneys in metabolic syndrome patients
Disease control Recruiting nowThis pilot study tests a 3-month program that combines online education, music-paced brisk walking, group discussions, and phone follow-ups for 40 adults with both metabolic syndrome and chronic kidney disease. The goal is to see if the program can reduce waist circumference and …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug aims to stop CMV from coming back after transplant
Disease control Recruiting nowThis study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from coming back in kidney or kidney/pancreas transplant patients who are at high risk. About 90 adults will take letermovir daily for 84 days and be followed for 6 months. The goal is to see if it red…
Phase: PHASE3 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lupus kidney trial aims for faster remission with drug cocktail
Disease control Recruiting nowThis study tests whether adding LUPKYNIS to standard biologic therapies (belimumab, obinutuzumab, or anifrolumab) can quickly improve kidney function in people with lupus nephritis. About 150 adults with biopsy-confirmed lupus kidney disease will receive the combination treatment…
Phase: PHASE4 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug targets tumor protein in first human tests
Disease control Recruiting nowThis early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can surgery after meds keep bladder cancer at bay?
Disease control Recruiting nowThis study looks at whether surgery to remove remaining cancer spots can help people with advanced bladder cancer that has been controlled by drug therapy. About 32 adults whose cancer has not spread widely will receive surgery on the main tumor and any other treatable spots. The…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cell shot aims to tame tough lupus cases
Disease control Recruiting nowThis early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …
Phase: PHASE1 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Digital care plans after kidney injury could save lives
Disease control Recruiting nowThis study tests whether a personalized digital care plan, given at hospital discharge, can reduce serious health problems after acute kidney injury (AKI). About 6,000 adults who had AKI in hospital will be randomly assigned to receive either the tailored plan or usual care. The …
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Donor immune cells take on tough viruses in transplant patients
Disease control Recruiting nowThis early-stage trial tests whether specially grown immune cells from a donor can safely help transplant patients fight off viral infections that standard treatments can't control. The cells target Epstein-Barr virus, cytomegalovirus, adenovirus, and BK virus. Up to 36 adults wh…
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced bladder cancer? drug targets specific gene mutations
Disease control Recruiting nowThis phase II trial is testing the drug pemetrexed in people with advanced bladder cancer or other solid tumors that have spread and carry certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if pemetrexed can shrink tumors. About 64 participants will receive the drug …
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a common bladder drug help boys with rare birth defect?
Disease control Recruiting nowThis study tests whether giving oxybutynin syrup early (starting at 3-6 months old) can improve bladder function in boys born with posterior urethral valves, a condition that blocks urine flow. Fifty boys who had valve surgery will be randomly assigned to receive either oxybutyni…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for liver metastases: immune booster combined with targeted chemo
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a peptide shield kidneys during bypass surgery? new trial aims to find out
Disease control Recruiting nowThis Phase 2 trial tests whether the drug LSALT peptide can prevent or reduce acute kidney injury in 240 adults undergoing on-pump cardiac surgery. Participants receive either the drug or a placebo before surgery, and doctors monitor kidney function for a week. The goal is to see…
Phase: PHASE2 • Sponsor: Arch Biopartners Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World check: do popular kidney stone & BPH devices hold up?
Disease control Recruiting nowThis study is tracking 238 adults who are already scheduled to have a procedure for kidney stones or an enlarged prostate (BPH) using Boston Scientific devices. The main goal is to see how often serious side effects happen with these tools in real-world use. Researchers will also…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Gut bacteria boosts immunotherapy in kidney cancer fight?
Disease control Recruiting nowThis phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy aims to fight bladder cancer without surgery
Disease control Recruiting nowThis study investigates whether combining the immunotherapy drug durvalumab with a cancer vaccine (S-488210/S-488211) can help people with a type of bladder cancer that has not responded to standard treatment. The trial includes adults with high-risk non-muscle invasive bladder c…
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shrinks kidney tumors before surgery in early trial
Disease control Recruiting nowThis study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on lupus and scleroderma in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for kidney cancer: experimental drug XmAb819 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug int…
Phase: PHASE1 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill aims to tame phosphorus in kidney dialysis patients
Disease control Recruiting nowThis study tests a new drug called TS-172 in 30 adults on peritoneal dialysis who have high phosphorus levels. Participants take the drug daily for several weeks to see if it can safely bring their phosphorus down to a target range. The goal is to find a better way to manage this…
Phase: PHASE3 • Sponsor: Taisho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to shield dialysis patients from deadly staph infections
Disease control Recruiting nowThis study tests a new drug called AZD7760 in healthy volunteers and people with end-stage kidney disease who are on dialysis. The goal is to see if the drug is safe and how the body processes it. If it works, it could help prevent serious staph infections that often occur in dia…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immunotherapy combo shows promise in bladder cancer trial
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder cancer surgery is safe and effective. About 150 people with muscle-invasive bladder cancer will receive durvalumab plus either ddMVAC or gemcitabine/cisplatin chemo…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cancer drug EXS74539 enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug duo aims to stop bladder cancer from coming back
Disease control Recruiting nowThis phase II trial is testing a combination of two drugs—disitamab vedotin given through a vein and mitomycin C placed directly into the bladder—in 30 people with a specific type of non-muscle-invasive bladder cancer that has a protein called HER2. The goal is to see if this tre…
Phase: PHASE2 • Sponsor: Shanxi Province Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with a type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder through a catheter. The main goals are to find the safest dose and see if people can toler…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could a drug combo shrink kidney tumors before surgery?
Disease control Recruiting nowThis study tests whether giving belzutifan alone, pembrolizumab alone, or both together before kidney surgery can help control advanced clear cell kidney cancer. About 10 people with locally advanced disease will receive the drugs before partial or total kidney removal. The main …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail takes on rare adrenal cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Lifestyle change trial targets waistline and kidneys in high-risk patients
Disease control Recruiting nowThis study tests whether a specially designed health behavior program can help people with metabolic syndrome and chronic kidney disease reduce their waist size and improve kidney function. Researchers will compare the program to usual care in 160 adults, measuring changes in wai…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a bone marrow transplant free kidney patients from lifelong pills?
Disease control Recruiting nowThis early-phase trial tests a combined kidney and bone marrow transplant from the same donor to help the body accept the new kidney without needing lifelong anti-rejection drugs. Up to 12 adults with kidney failure will receive the treatment. The goal is to see if this approach …
Phase: EARLY_PHASE1 • Sponsor: Tatsuo Kawai, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kidney patients: diabetes drugs tested to fight nephrotic syndrome
Disease control Recruiting nowThis study tests whether two diabetes drugs (dapagliflozin and empagliflozin) can help adults with nephrotic syndrome, a kidney condition that causes protein leakage and swelling. About 75 participants will receive either one of these drugs plus standard care, or standard care al…
Phase: PHASE2, PHASE3 • Sponsor: Mansoura University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New tool may spare women unnecessary organ removal during bladder cancer surgery
Disease control Recruiting nowThis study tests a decision tool to help select women with bladder cancer who can safely keep their reproductive organs during bladder removal surgery. Currently, standard surgery removes the bladder, uterus, ovaries, and part of the vagina, which can harm sexual health, mental h…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Virus therapy takes on tough colorectal cancer in new trial
Disease control Recruiting nowThis study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (…
Phase: PHASE2 • Sponsor: Oncolytics Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take on rare solid tumors in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug targets HER2 cancers in broad trial
Disease control Recruiting nowThis phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to outsmart chemo in tough bladder cancer
Disease control Recruiting nowThis study compares a new drug, izalontamab brengitecan, against standard platinum-based chemotherapy in 470 people with metastatic urothelial cancer that has worsened after immunotherapy. The goal is to see if the new drug can slow cancer growth or improve survival. Participants…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill for diabetes and kidney disease enters first human tests
Disease control Recruiting nowThis early-stage study tests an experimental oral drug called ONO-3310 in healthy Japanese men and in people with type 2 diabetes who also have chronic kidney disease. The main goal is to check the drug's safety and how the body processes it. Researchers will also measure its eff…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Gut bacteria boosts immunotherapy in kidney cancer trial
Disease control Recruiting nowThis phase 2 trial tests whether adding a live bacteria product called CBM588 to the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. About 62 adults with high-risk clear cell or sarcomatoid kidney cancer will receive either pembroli…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Personalized vaccine + immunotherapy aims to stop bladder cancer return
Disease control Recruiting nowThis phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) to the immunotherapy drug nivolumab can prevent high-risk bladder cancer from coming back after surgery. About 62 participants will receive either the combination or nivolumab alone. The st…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare kidney diseases: three drugs enter trial
Disease control Recruiting nowThis study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Injection vs sling: which works better for leaky bladder?
Disease control Recruiting nowThis study compares two procedures for stress urinary incontinence (leaking urine with cough, sneeze, or exercise) in 358 women. One group gets a bulking agent injection to thicken the urethra lining; the other gets a small mesh sling to support the urethra. The goal is to see wh…
Phase: NA • Sponsor: NICHD Pelvic Floor Disorders Network • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to protect dialysis Patients' hearts
Disease control Recruiting nowThis study tests a drug called CSL300 in people with end-stage kidney disease who are on dialysis and have signs of inflammation. The goal is to see if it can reduce the risk of heart attacks or heart-related death. About 3110 adults will take part, and half will get the drug whi…
Phase: PHASE2, PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for bladder cancer patients: radiotherapy trial aims to improve survival and quality of life
Disease control Recruiting nowThis phase III trial tests whether adding local radiotherapy to standard care helps bladder cancer patients who are not eligible for curative treatment live longer and feel better. About 248 participants will be randomly assigned to receive either standard care alone or standard …
Phase: NA • Sponsor: Umeå University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a Pre-Transplant weight loss program improve kidney transplant success?
Disease control Recruiting nowThis study tests a program that helps people with obesity who are waiting for a kidney transplant lose weight. Participants will receive education, a calorie tracking app, a continuous glucose monitor, a weight scale, and a food scale. The goal is to see if this program is practi…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kidney disease: first human trial of PYC-003 begins
Disease control Recruiting nowThis study is the first time a new drug called PYC-003 is being tested in humans. It is for people with a genetic kidney disease that causes cysts to grow and damage the kidneys. The trial will first test the drug in healthy volunteers to check safety, then in patients with the d…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kidney cancer? early trial launches
Disease control Recruiting nowThis early-stage study tests a new drug, BMS-986506, in people with advanced clear cell kidney cancer that has not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. About 125 participants will take the drug alone to see…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a simple infusion save transplanted kidneys from a stealthy virus?
Disease control Recruiting nowThis study tests whether reducing anti-rejection drugs, with or without an extra treatment called IVIG, can better control BK virus in kidney transplant patients. BK virus can damage the new kidney and lead to transplant failure. About 280 adults and children who have a kidney or…
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug enzelkitug enters first human trials
Disease control Recruiting nowThis early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a newer drug protect heart health after kidney transplant?
Disease control Recruiting nowThis study looks at kidney transplant patients who take immunosuppressants to prevent organ rejection. It compares the effects of belatacept, a newer drug, against standard anticalcineurins on blood vessel function. The goal is to see if belatacept improves vascular health and re…
Phase: PHASE4 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Parkinson's drug repurposed to fight kidney disease?
Disease control Recruiting nowThis study tests whether a rotigotine skin patch, a drug used for Parkinson's disease, is safe for people with autosomal dominant polycystic kidney disease (ADPKD). ADPKD causes fluid-filled cysts in the kidneys and can lead to kidney failure. The trial will give 120 adults eithe…
Phase: PHASE2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
No clamps, no stitches: new robotic surgery aims to save more kidney function
Disease control Recruiting nowThis study tests a new robotic surgery technique for kidney cancer that avoids clamping blood vessels and using stitches to close the kidney. The goal is to preserve as much kidney function as possible and reduce the risk of long-term kidney disease. About 59 adults with small ki…
Phase: NA • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Which drain first? trial tests best emergency move for blocked kidney
Disease control Recruiting nowThis study looks at people with a sudden kidney blockage from a stone in their only working kidney. Doctors will randomly use either a tube placed through the bladder or one through the back to drain urine. The goal is to see which method helps kidney function recover better and …
Phase: NA • Sponsor: Beni-Suef University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
App helps manage side effects of kidney cancer combo therapy
Disease control Recruiting nowThis study tests whether a digital app that tracks symptoms weekly can help doctors better manage side effects in people with advanced kidney cancer taking cabozantinib and nivolumab. About 83 patients will use the app to report how they feel, and doctors can adjust treatment bas…
Phase: PHASE4 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Bladder cancer trial aims to save more of the bladder
Disease control Recruiting nowThis study is for people with muscle-invasive bladder cancer that has not spread. It tests whether removing only the part of the bladder with cancer (partial cystectomy) plus nearby lymph nodes works as well as removing the whole bladder. Participants get standard chemotherapy be…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New antibody drug aims to shrink advanced tumors in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
10-Year check: does this sling really fix leakage?
Disease control Recruiting nowThis study follows about 195 women for up to 10 years after they receive a mesh sling (GYNECARE TVT ABBREVO) to treat stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). The main goal is to see how many women are still dry after 5-10 years. Partici…
Sponsor: Ethicon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill takes aim at hard-to-treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…
Phase: PHASE1 • Sponsor: Iambic Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for FSGS: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could amniotic membrane ease bladder pain? new trial seeks answers
Disease control Recruiting nowThis study tests whether injecting a substance made from donated amniotic membrane into the bladder can reduce pain and urgency in women with interstitial cystitis (painful bladder syndrome). One hundred women who have not gotten better with other treatments will receive either t…
Phase: PHASE2, PHASE3 • Sponsor: David Sheyn • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Caffeine boost may shield preterm Babies' kidneys
Disease control Recruiting nowThis study tests whether giving extra caffeine to very premature babies (born before 30 weeks) can improve kidney oxygen levels and reduce kidney injury. About 114 babies already receiving standard caffeine will get either an extra dose or a placebo. Researchers will monitor kidn…
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New targeted therapy aims to keep bladder cancer at bay
Disease control Recruiting nowThis study compares a new drug delivery system (TAR-210) that releases erdafitinib directly into the bladder versus standard chemotherapy for people with intermediate-risk non-muscle invasive bladder cancer that has certain genetic changes (FGFR alterations). About 641 participan…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cells take on BK virus in vulnerable transplant patients
Disease control Recruiting nowThis study tests whether specially grown immune cells (called cytotoxic T lymphocytes) can safely lower BK virus levels in 20 transplant patients with weakened immune systems. Participants have had a stem cell or kidney transplant and show signs of BK virus infection. The goal is…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New bladder cancer treatment TAR-200 put to the test in everyday clinics
Disease control Recruiting nowThis study is tracking 150 people with early-stage bladder cancer who are receiving TAR-200, a treatment placed directly into the bladder. Researchers want to see how long it takes for the cancer to come back or get worse in real-world settings, not just in controlled trials. The…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for bladder cancer: experimental drug trial now recruiting
Disease control Recruiting nowThis study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Modified virus boosts immunotherapy in kidney cancer trial
Disease control Recruiting nowThis phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Stem cell reset could open door to kidney transplants for 'Impossible' patients
Disease control Recruiting nowThis early-phase trial tests whether a powerful immune reset using a patient's own stem cells can clear the antibodies that block them from receiving a kidney transplant. Ten highly sensitized adults with end-stage kidney disease will undergo intense conditioning to wipe out thei…
Phase: PHASE1, PHASE2 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Last-Resort cancer drug made available for patients with specific gene mutations
Disease control AVAILABLEThis program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …
Sponsor: xCures • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cancer drug combo trial launches for Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…
Phase: PHASE1 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Pee test could replace needles for bladder cancer detection
Diagnosis Recruiting nowThis study is testing whether a urine test can accurately detect urothelial carcinoma, a type of cancer that includes bladder cancer. Researchers are comparing the test results to standard tissue biopsies in 800 adults with blood in their urine and suspicious imaging findings. If…
Sponsor: Henan Provincial People's Hospital • Aim: Diagnosis
Last updated Jul 03, 2026 23:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
A simple urine test could revolutionize bladder cancer detection
Diagnosis Recruiting nowThis study is testing a new urine test called UroAmp to see if it can accurately detect bladder cancer and monitor for its return. Researchers will collect urine and tumor samples from 2,500 people being evaluated or treated for bladder cancer or related conditions. The goal is t…
Sponsor: Convergent Genomics, Inc. • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New test could make diagnosis of thirst disorders easier for patients
Diagnosis Recruiting nowThis study compares a new diagnostic test using mannitol infusion to the standard hypertonic saline test for diagnosing the cause of polyuria-polydipsia syndrome (excessive urination and thirst). Researchers will enroll 144 adults to see if the mannitol test is as accurate and mo…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Urine test may spot kidney danger early in septic shock
Diagnosis Recruiting nowThis study investigates whether a urine test called Nephrocheck can predict which patients with septic shock will develop severe acute kidney injury. The test measures two markers of kidney damage (TIMP2 and IGFBP7). Researchers will analyze data from previous studies involving a…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive antibody hunt: could a new scan outsmart hidden kidney cancer?
Diagnosis Recruiting nowThis Phase II trial tests whether a special PET/CT scan using a radioactive tracer called 89Zr-DFO-girentuximab can find recurrent clear cell renal cell carcinoma after surgery better than standard contrast-enhanced CT. The tracer attaches to a protein (CAIX) on kidney cancer cel…
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple ultrasound biopsy replace surgery for bladder cancer staging?
Diagnosis Recruiting nowThis study is testing whether an ultrasound-guided core needle biopsy can accurately determine the stage of bladder cancer. Researchers will compare the biopsy results with the final stage found during standard surgery. The goal is to see if this less invasive method can be a rel…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
AI learns to spot bladder cancer under blue light
Diagnosis Recruiting nowThis study collects video recordings and data from 500 patients undergoing blue light cystoscopy, a procedure where a drug makes cancer cells glow. The goal is to train an artificial intelligence (AI) algorithm to detect bladder lesions in real time, helping doctors make more acc…
Sponsor: Photocure • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New ultrasound technique aims to spot cancer more clearly
Diagnosis Recruiting nowThis study is testing a new ultrasound imaging method called Contrast Enhanced Super-Resolution (CESR) to see if it can better detect and tell apart cancerous and non-cancerous lesions in the breast, liver, and kidney. It involves 40 participants: 10 healthy volunteers to fine-tu…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to shield kidneys from heart surgery harm
Prevention Recruiting nowThis study tests a drug called BX-001N to see if it can prevent acute kidney injury in people having heart surgery. About 40 adults will receive either a low dose, high dose, or a placebo. The goal is to see if the drug can keep kidneys working well after surgery.
Phase: PHASE2 • Sponsor: Bilix Co.,Ltd. • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Mail-Order heart screening could save thousands – but does it work?
Prevention Recruiting nowThis study is testing whether a home-based screening kit can identify hidden heart risks better than standard doctor visits. 45,000 adults in Sweden aged 50-75 will either receive a home blood pressure monitor, a finger-prick blood test, and a health questionnaire, or continue wi…
Phase: NA • Sponsor: Johan Sundström • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Could amniotic membrane make mesh surgery safer for women?
Prevention Recruiting nowThis study looks at whether adding a human amniotic membrane graft to standard mesh surgery can lower the risk of mesh exposure, a common complication. About 330 women with pelvic organ prolapse or stress urinary incontinence will take part. The goal is to see if the membrane hel…
Phase: NA • Sponsor: Hospital General de Agudos J. M. Penna • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Could a single drug shield kidneys during heart surgery?
Prevention Recruiting nowThis study tests whether the drug R2R01 can prevent acute kidney injury in people at high risk who are having heart surgery with a heart-lung machine. Participants receive either R2R01 or a placebo before and after surgery. The goal is to see if the drug reduces kidney damage and…
Phase: PHASE2 • Sponsor: River 2 Renal Corp. • Aim: Prevention
Last updated Jun 27, 2026 13:02 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Zinc pills may boost botox for bladder control — new trial underway
Symptom relief Recruiting nowThis study tests whether taking zinc supplements before a Botox injection can improve results for women with overactive bladder. 72 women will receive either zinc or a placebo pill for five days before their Botox treatment. Researchers will track how many need another injection …
Phase: PHASE2 • Sponsor: Endeavor Health • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Can a home visit program get kidney patients off the sidelines?
Symptom relief Recruiting nowThis study tests a program called CAPABLE Transplant, where an occupational therapist, nurse, and handy worker visit people at home over 4 months. The goal is to help kidney transplant candidates who are currently inactive on the waitlist become active again, and to improve their…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
New anesthesia cocktail aims to get kidney surgery patients home faster
Symptom relief Recruiting nowThis study compares a combination of anesthesia methods (multimodal) to standard anesthesia for people having robotic kidney surgery for cancer. The goal is to see if the special approach helps patients recover more quickly, have less pain, and go home sooner. About 80 adults wil…
Phase: NA • Sponsor: Fundacio Puigvert • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New vacuum tool may improve kidney stone surgery
Symptom relief Recruiting nowThis study compares two surgical methods for removing kidney stones: one using a vacuum-assisted sheath and the other using a standard sheath. About 90 adults with stones between 10-25 mm will be randomly assigned to one of the two procedures. The goal is to see which method clea…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Smart tracking may boost kidney stone shockwave success
Symptom relief Recruiting nowThis study compares two versions of a shockwave machine for breaking kidney stones: one with stone tracking and one without. About 126 adults with a single kidney stone (6-15 mm) will be randomly assigned to either group. The goal is to see if the tracking feature helps more peop…
Phase: NA • Sponsor: Storz Medical AG • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
New gadget aims to treat leaky bladder from home
Symptom relief Recruiting nowThis study tests a medical device (a perineal probe connected to a mobile app) for women with stress urinary incontinence. Participants use the device at home for 15 minutes, three times a week, plus two sessions with a physiotherapist. The goal is to see if this approach works a…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Opioid-Free anesthesia: a safer way to go under the knife?
Symptom relief Recruiting nowThis study compares opioid-free anesthesia to standard opioid-based anesthesia in 600 adults undergoing urological abdominal surgery. The goal is to see if avoiding opioids during surgery reduces the need for painkillers afterward and lowers side effects like nausea. Patients wil…
Phase: NA • Sponsor: Jagiellonian University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a simple breathing change make kidney stone surgery easier?
Symptom relief Recruiting nowThis study compares two breathing machine settings during kidney stone surgery to see which one gives surgeons a clearer, steadier view inside the kidney. Sixty adults having elective surgery will be randomly assigned to either normal or low tidal volume ventilation. The goal is …
Phase: NA • Sponsor: Hitit University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New pill could help women stop leaking urine during exercise
Symptom relief Recruiting nowThis study tests whether a once-daily pill called orforglipron can reduce stress urinary incontinence (leaking urine during movement) in women with obesity or overweight. About 1000 adult women will receive either the drug or a placebo for about 58 weeks. The main goal is to see …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could a monthly symptom check improve life for kidney patients?
Symptom relief Recruiting nowThis study tests whether having patients with advanced chronic kidney disease (stages 4 and 5) report their symptoms monthly through an electronic questionnaire, with results shared with their kidney doctors, can improve symptom management and quality of life. The trial will enro…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Could less dialysis at first be better? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether starting peritoneal dialysis (a home-based treatment for kidney failure) at a low dose and gradually increasing it can improve patients' quality of life compared to the standard full-dose approach. About 224 adults new to dialysis will take part. The goal…
Phase: NA • Sponsor: The University of Queensland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to tame Chemo's nerve damage in bladder cancer
Symptom relief Recruiting nowThis early-phase study tests an investigational drug called GB-4362 given alongside standard treatments (enfortumab vedotin and pembrolizumab) for adults with advanced or metastatic urothelial cancer. The goal is to see if GB-4362 can safely neutralize a chemotherapy byproduct th…
Phase: PHASE1 • Sponsor: Generate Biomedicines • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New device trial offers hope for bladder and bowel leakage
Symptom relief Recruiting nowThis study is testing a new external device (Axonics ETS-02) to see if it is safe and works for people with overactive bladder or fecal incontinence. About 75 adults will wear the device for a short trial period. The goal is to check if the device stays attached and works properl…
Phase: NA • Sponsor: Axonics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New device aims to quiet overactive bladder in men
Symptom relief Recruiting nowThis study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …
Phase: NA • Sponsor: Axonics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study tests simple drainage trick to speed up bladder stone surgery
Symptom relief Recruiting nowThis study looks at whether adding a small drainage tube in the belly during surgery for large bladder stones (over 2 cm) can make the operation faster and easier. About 140 adults will be randomly assigned to get the standard procedure alone or with the extra tube. The main goal…
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New program aims to help cancer patients stick with immunotherapy
Symptom relief Recruiting nowThis study tests a navigation program for cancer patients starting immunotherapy. The program helps with essential needs like food, transportation, and housing, and tracks side effects. Researchers want to see if this support helps patients continue their treatment and improves t…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New suction device may improve kidney stone removal
Symptom relief Recruiting nowThis study tests two different tubes used during kidney stone surgery to see which one works better. One tube has suction to remove stone pieces and fluid, while the other does not. Researchers will track how many patients are stone-free after surgery and compare complication rat…
Phase: NA • Sponsor: Hitit University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New study tests which nerve block eases kidney surgery pain best
Symptom relief Recruiting nowThis study compares two types of ultrasound-guided nerve blocks for pain control after open kidney removal surgery. Ninety adults will receive either a rhomboid intercostal sub-serratus plane block or an external oblique intercostal block. Researchers will measure how long it tak…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New hope for teens on dialysis: drug targets severe itching
Symptom relief Recruiting nowThis study tests a medicine called difelikefalin in teenagers aged 12 to 17 who are on hemodialysis and have moderate to severe itching. The goal is to see if the drug is safe and how much gets into the blood. About 18 teens will receive the medicine up to 4 times a week for 12 w…
Phase: PHASE2 • Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Tiny tubes, big difference: study seeks best stent for stone patients
Symptom relief Recruiting nowThis study compares four different ureteral stents (small tubes placed in the ureter) to find which one causes the fewest symptoms after laser surgery for kidney stones. About 272 adults who need a stent after stone removal will be randomly assigned to one of four stent types. Re…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New tool helps pharmacists decide when antibiotics are needed for bladder infections
Symptom relief Recruiting nowThis study tests whether a shared decision-making tool can help pharmacists and patients better understand when antibiotics are truly needed for uncomplicated cystitis (bladder infection). About 506 women with symptoms will be enrolled. The goal is to reduce unnecessary antibioti…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Hip workout may cut leaks for women with bladder weakness
Symptom relief Recruiting nowThis study tests whether adding hip abductor exercises to standard pelvic floor training can reduce urine leaks in women with stress urinary incontinence. About 78 women will be split into two groups: one does only pelvic floor exercises, the other adds hip exercises at home. The…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy could speed up kidney stone passage
Symptom relief Recruiting nowThis study tests two medications, mirabegron and tamsulosin, to see which works best for helping people pass ureteral stones and reducing pain. 500 adults with stones between 4-10 mm will be randomly assigned to one of four groups: mirabegron alone, tamsulosin alone, both drugs t…
Phase: PHASE4 • Sponsor: Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New study tests simple exercises to stop leakage after childbirth
Symptom relief Recruiting nowThis study compares two types of core exercises—hypopressive training and transversus abdominis focused training—to see which better reduces urinary incontinence and improves pelvic floor function and quality of life in women after childbirth. Sixty women who had a normal vaginal…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to stop daytime accidents in kids
Symptom relief Recruiting nowThis study looks at whether a combination of two drugs (solifenacin and mirabegron) at low doses works better than a high dose of either drug alone for children aged 5 to 14 with daytime wetting. About 236 children who did not fully respond to low-dose single drugs will be random…
Phase: PHASE3 • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Lying at an angle may speed up kidney stone surgery
Symptom relief Recruiting nowThis study tests two different ways of positioning patients during surgery for stones in the upper part of the ureter. One position uses a slight head-down tilt to keep stones from moving back into the kidney, while the other tilts the patient to help clear stones from the kidney…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can simple exercises fix postpartum bladder leaks? new study tests two methods
Symptom relief Recruiting nowThis study compares two types of exercises—hypopressive exercises and the Paula method—to see which better helps postpartum women with urinary incontinence. Sixty women who had a vaginal delivery and leak urine at least once a week will do one of the two exercises twice a week fo…
Phase: NA • Sponsor: Riphah International University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Laser vs bipolar: which surgery best tames an oversized prostate?
Symptom relief Recruiting nowThis study compares three different surgical techniques for men with very large prostates (over 100 mL) who have severe urinary symptoms. Ninety men will be randomly assigned to receive either thulium fiber laser, holmium laser, or bipolar electrosurgery. Researchers will measure…
Phase: NA • Sponsor: Tanta University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can a 13-Week therapy program ease anxiety for dialysis patients?
Symptom relief Recruiting nowThis pilot study tests a 13-week Dialectical Behavioural Therapy (DBT) skills training program for Canadians who have recently started or will soon start facility-based hemodialysis. The goal is to see if the program is feasible and helpful for improving mental health and reducin…
Phase: NA • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Botox shot into bladder during prostate surgery may ease urgent bathroom trips
Symptom relief Recruiting nowThis study tests whether injecting Botox into the bladder wall during a standard prostate surgery (HoLEP) can better control overactive bladder symptoms like sudden urges to urinate and leakage. About 66 men aged 18-89 with these symptoms will be randomly assigned to get Botox or…
Phase: PHASE2, PHASE3 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Lupus secrets revealed: major study tracks disease over time
Knowledge-focused Recruiting nowThis study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Researchers track rare thyroid cancer to uncover its secrets
Knowledge-focused Recruiting nowThis study follows children and adults with medullary thyroid cancer (MTC), often linked to a genetic condition called MEN2. Researchers will track how the cancer grows and affects health over time using regular check-ups, blood tests, and imaging. No treatment is given, but part…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Massive kidney disease registry aims to uncover best treatments
Knowledge-focused Recruiting nowThis observational study will follow 3,000 Chinese adults with chronic kidney disease (CKD) to see how they are treated in real-world clinics and what happens to their health over time. Researchers will track medications, kidney function, heart risks, and hospital visits. The goa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists hunt for gene behind rare kidney cancer syndrome
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists bank tumors and blood to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch major study to uncover secrets of kidney autoimmunity
Knowledge-focused Recruiting nowThis study follows up to 2000 people with immune-related kidney diseases, such as nephrotic syndrome and lupus nephritis. Researchers will collect medical history, lab tests, and blood or urine samples to better understand these conditions. The goal is to learn more about causes …
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New study tracks Belimumab's Long-Term kidney benefits in lupus patients
Knowledge-focused Recruiting nowThis study follows 300 adults with lupus nephritis who are already taking belimumab as part of their routine care. Researchers will track kidney function for up to 5 years to see how well the drug preserves renal health and prevents the need for dialysis or transplant. The goal i…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Could the type of anesthesia affect kidney transplant success?
Knowledge-focused Recruiting nowThis study compares two anesthesia methods—general anesthesia with sevoflurane and combined spinal-epidural anesthesia—in adults receiving a kidney transplant. Researchers will measure blood markers related to cell damage and protection to see if one method better shields the new…
Phase: NA • Sponsor: University of Gaziantep • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists seek better way to measure Body's energy use
Knowledge-focused Recruiting nowThis natural history study will look at how metabolism relates to body size and composition in 2,000 people aged 2 and older, including healthy volunteers and those with conditions like diabetes, obesity, or cancer. Participants will stay in the hospital for two days to undergo v…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New drug AZD4248 tested for kidney disease in first human trials
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called AZD4248 in healthy volunteers and people with chronic kidney disease and type 2 diabetes. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
Knowledge-focused Recruiting nowThis study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists probe kidney damage after heart surgery to find clues for prevention
Knowledge-focused Recruiting nowThis study is observing 200 adults scheduled for heart surgery to understand why some develop acute kidney injury afterward. Researchers will collect blood and urine samples before and after surgery to measure biomarkers linked to kidney damage. No experimental treatments are giv…
Phase: NA • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive cancer database aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Live biopsy study aims to predict immunotherapy response in cancer patients
Knowledge-focused Recruiting nowThis study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study tracks Finerenone's impact on kidney risk in diabetic patients
Knowledge-focused Recruiting nowThis study will follow 500 adults with chronic kidney disease and type 2 diabetes who are taking finerenone, a drug that helps protect the kidneys and heart. Researchers want to see if a tool called the Klinrisk score, which estimates the risk of kidney disease getting worse, imp…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Bladder cancer study aims to end treatment guesswork
Knowledge-focused Recruiting nowThis study looks at two common treatments for a type of bladder cancer that keeps coming back: treatments that keep the bladder (like medicine placed directly into the bladder) versus surgery to remove the bladder. The goal is to see which option is better for patients' wallets, …
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Teen diabetes study seeks to uncover hidden triggers of kidney damage
Knowledge-focused Recruiting nowThis research study follows 500 adolescents with type 2 diabetes to understand why some develop kidney problems. Researchers are looking at biological factors like blood sugar and blood pressure, as well as psychological and social factors such as stress, mental health, and pover…
Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New biomarker study aims to spot lupus kidney disease earlier
Knowledge-focused Recruiting nowThis study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Russian bladder cancer care under the microscope: new study tracks Real-World treatments
Knowledge-focused Recruiting nowThis study is observing how bladder cancer is treated in Russia and how common certain markers (HER2 and PD-L1) are in different stages. Researchers will look at medical records of 600 people with bladder cancer to see what treatments they receive and how the disease progresses. …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to unlock BK virus mysteries in kidney transplants
Knowledge-focused Recruiting nowThis registry study is collecting blood and urine samples from 60 kidney transplant recipients who have BK virus infection. Researchers want to understand how the immune system responds to the virus and how immunosuppressive drugs affect that response. The goal is to find better …
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Pelvic mesh registry aims to track outcomes over a decade
Knowledge-focused Recruiting nowThis study is a long-term registry that will follow 1,000 women who receive pelvic mesh products for stress urinary incontinence or pelvic organ prolapse. Researchers will track how well the mesh works and any complications over 5 to 10 years. The goal is to gather real-world dat…
Sponsor: Ethicon, Inc. • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Does diabetes make fat problems worse in kidney disease? new study investigates
Knowledge-focused Recruiting nowThis observational study will compare blood fat (lipid) levels in 200 adults with chronic kidney disease—half with diabetes and half without. Researchers want to find out if having diabetes leads to worse fat problems in these patients. Participants will fast for 10 hours before …
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New drug iptacopan tested in Real-Life PNH patients
Knowledge-focused Recruiting nowThis study looks at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice. Researchers will track 50 Italian patients for 12 months to see if their anemia improves and if they need fewer blood transfusions. The go…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists launch biobank to unlock secrets of rare vasculitis
Knowledge-focused Recruiting nowThis study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease f…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can we fix the immune system in kidney disease? lab study begins
Knowledge-focused Recruiting nowThis study looks at how well the immune system works in people with end-stage kidney disease. Researchers will take blood samples from 100 patients and healthy donors to study T-cells, a key part of the immune system. They also plan to test a lab technique to restore T-cell funct…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study uses motion capture to understand balance problems in MS
Knowledge-focused Recruiting nowThis study is observing 40 adults with multiple sclerosis to see how clinical tests of balance and walking relate to detailed motion-capture measurements. Participants will attend one session where they walk on force plates and perform balance tasks while cameras track their move…
Sponsor: University of Patras • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study aims to spot eye damage early in rare vasculitis patients
Knowledge-focused Recruiting nowThis study looks at how ANCA-associated vasculitis affects the eyes. Researchers will use a special imaging test called OCT angiography to examine blood vessels in the eyes of 70 participants. The goal is to better understand and detect eye involvement early, which could help pre…
Sponsor: Military Institute od Medicine National Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
800-Patient study aims to uncover best treatments for kidney disease
Knowledge-focused Recruiting nowThis observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive kidney cancer database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is building a large French registry of up to 30,000 kidney cancer patients. It collects detailed medical information and biological samples over time to support research. The goal is to better understand the disease and improve patient care, not to test a new treatment…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
NIH launches major study to unlock secrets of rare bone diseases
Knowledge-focused Recruiting nowThis study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
No new drug, just watching: kidney transplant patients monitored after experimental therapy
Knowledge-focused Recruiting nowThis study is a long-term follow-up for 20 people with chronic kidney disease who received an experimental drug called vonsetamig and then had a kidney transplant in an earlier study. No new treatment is given here. Researchers will track how the drug affects the body and monitor…
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive study aims to unlock secrets of parathyroid diseases
Knowledge-focused Recruiting nowThis study follows up to 3,000 people who have, are at risk for, or are related to someone with a parathyroid disorder. Researchers will collect medical records, questionnaires, and samples like blood and saliva to learn what causes these conditions and how they change over time.…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Kidney disease biobank aims to unlock new treatments
Knowledge-focused Recruiting nowThis study is collecting blood, urine, and kidney tissue samples from 144 children and adults with a kidney condition called nephrotic syndrome. The goal is to build a large database and sample collection to study how the immune system and kidney cells interact. Researchers hope …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for clues to stop kidney rejection
Knowledge-focused Recruiting nowThis study looks at a type of immune cell called memory B cells in people waiting for a kidney transplant who have certain antibodies. Researchers want to understand why some of these cells cause rejection while others don't. They will analyze blood samples from 51 patients to fi…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Lifestyle overhaul may tame inflammation in diabetic kidney patients
Knowledge-focused Recruiting nowThis study looks at how a 12-week lifestyle change affects inflammation and stress markers in 60 overweight adults with type 2 diabetes and moderate chronic kidney disease. Participants will follow a modified diet and exercise plan. The goal is to see if these changes can reduce …
Phase: NA • Sponsor: Badr University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Diabetes and vitamin c loss: scientists launch major study to solve the mystery
Knowledge-focused Recruiting nowThis study aims to find out why people with diabetes often have lower vitamin C levels in their blood. Researchers will measure vitamin C in blood, urine, and cells from 5,000 adults with and without diabetes. They will also look at genes that control vitamin C transport. The goa…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a lower dose of rivaroxaban be safer for kidney patients on dialysis?
Knowledge-focused Recruiting nowThis study is testing three different low doses of the blood thinner rivaroxaban in 10 adults on chronic hemodialysis. The goal is to see how the drug behaves in the body and how much it thins the blood, to find a dose that might lower bleeding risks. Participants will take each …
Phase: PHASE3 • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Rare gene study aims to unlock kidney cancer risks
Knowledge-focused Recruiting nowThis study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive device registry aims to improve patient safety
Knowledge-focused Recruiting nowThis study is a registry that collects information on the safety and effectiveness of Medtronic medical devices already on the market. It will include up to 100,000 people who have or will receive a Medtronic product for conditions like heart, nerve, or digestive disorders. The g…
Sponsor: Medtronic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
50,000 patients to reveal how new kidney drug works in real life
Knowledge-focused Recruiting nowThis observational study will follow 50,000 people in Asia and the United States who have chronic kidney disease and type 2 diabetes and are already taking finerenone as part of their regular care. Researchers will collect data from electronic health records and insurance claims …
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
50,000 childhood cancer survivors join landmark Long-Term health study
Knowledge-focused Recruiting nowThis study follows about 50,000 people who survived childhood cancer (diagnosed before age 21 between 1970 and 1999) and 10,000 of their siblings. Researchers want to understand how cancer treatments like radiation, chemotherapy, and surgery affect health years later. By comparin…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New device may improve bladder cancer surgery accuracy
Knowledge-focused Recruiting nowThis study tests a redesigned surgical tool for removing bladder tumors. Researchers will use the device on bladder specimens from 25 patients who need their bladder removed. The goal is to see if the modified device provides better tissue samples for pathology, helping doctors a…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive study aims to unlock mysteries of rare blood vessel disease
Knowledge-focused Recruiting nowThis study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
AI could help predict risks after bladder cancer surgery
Knowledge-focused Recruiting nowThis study looks at how other medical conditions (comorbidities) affect recovery and survival in 500 bladder cancer patients after bladder removal surgery. Researchers will use artificial intelligence to analyze patient data and find patterns that could help doctors make better t…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Obesity blocks kidney transplants: new study investigates why
Knowledge-focused Recruiting nowThis study follows 100 obese patients starting dialysis to understand why they are less likely to receive a kidney transplant. Researchers will track health changes over two years and compare them to non-obese patients. The goal is to identify barriers and improve access to trans…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could spinal anesthesia cut bleeding risk in prostate surgery?
Knowledge-focused Recruiting nowThis study compares spinal anesthesia to general anesthesia in men undergoing open simple prostatectomy for an enlarged prostate. The goal is to see if spinal anesthesia leads to less postoperative bleeding, such as fewer blood transfusions or less need for bladder irrigation. Ei…
Phase: NA • Sponsor: Hitit University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Yale researchers dive into lymph nodes to unlock kidney cancer secrets
Knowledge-focused Recruiting nowThis study looks at the immune cells in the lymph nodes near kidney tumors to learn how the body fights the cancer. Researchers will analyze tissue samples from 10 adult kidney cancer patients to find clues about why some treatments work and others don't. The goal is to discover …
Phase: NA • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple home test catch kidney disease earlier in diabetes patients?
Knowledge-focused Recruiting nowThis study looks at whether sending home test kits or ordering standard lab tests can help more people with type 2 diabetes get screened for chronic kidney disease (CKD). About 750 adults who are missing key kidney function tests will be enrolled. The goal is to see if these appr…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New drug INCB123667 tested in kidney patients for safety
Knowledge-focused Recruiting nowThis early-stage study looks at how safe a new drug called INCB123667 is for people with severe kidney disease or kidney failure. Researchers will measure how the drug moves through the body and check for side effects. The study involves 16 adults aged 18 to 85.
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
HER2 test showdown: which lab method is best for chinese cancer patients?
Knowledge-focused Recruiting nowThis study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Protein shake could unlock better kidney tests
Knowledge-focused Recruiting nowThis study is testing how reliable a kidney function test called renal functional reserve is. Researchers will give healthy people and those with kidney problems a protein shake, then take blood and urine samples to see how well their kidneys respond. The goal is to see if this t…
Phase: NA • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New registry aims to unlock secrets of kidney disease that starts in childhood
Knowledge-focused Recruiting nowThis study creates a registry to collect health information from people with Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common genetic cause of kidney failure. While ADPKD was once thought to only affect adults, researchers now know it begins in childhood, but…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Korean kidney study tracks Real-World use of finerenone
Knowledge-focused Recruiting nowThis study watches 500 adults in South Korea who have chronic kidney disease and type 2 diabetes and are taking finerenone as part of their normal care. Researchers will collect information from medical records and doctor visits over up to 12 months to see why doctors prescribe i…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New registry aims to unlock secrets of rare Kidney-Liver diseases
Knowledge-focused Recruiting nowThis study is creating a central database and tissue bank for rare diseases affecting the kidneys and liver, such as ARPKD and Joubert syndrome. Researchers will collect medical information, genetic samples, and tissues from 200 participants to help doctors and scientists better …
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
French study aims to uncover hidden patterns in rare kidney disease
Knowledge-focused Recruiting nowThis study is gathering information from 400 adults in France diagnosed with membranous nephropathy, a rare kidney condition. Researchers will track how the disease progresses over one year, looking at remission rates and possible environmental or genetic risk factors. The goal i…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Diabetes drug shows promise for kidney protection in new study
Knowledge-focused Recruiting nowThis study looks at how an FDA-approved diabetes drug, Canagliflozin (Invokana), might protect the kidneys in people with type 2 diabetes. Twenty adults aged 18-80 with type 2 diabetes for at least 3 years will take the drug daily for 6 months. Researchers will use kidney biopsie…
Phase: PHASE4 • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
5,000 cancer patients enrolled to uncover proton Therapy's hidden risks
Knowledge-focused Recruiting nowThis study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Could your genes cause pelvic pain? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to find out if chronic pelvic pain conditions like prostatitis and interstitial cystitis can be inherited. Researchers will collect DNA and urine from 500 participants, including family members, to look for genetic links. The goal is to better understand the cause…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Kidney disease mystery: scientists launch massive data hunt
Knowledge-focused Recruiting nowThis study is for people with rare kidney diseases like Minimal Change Disease, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy. Researchers will collect health information and biological samples from 1,200 participants over many years. The goal is to better unders…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study aims to set strength standards for dialysis patients
Knowledge-focused Recruiting nowThis study measures hip muscle strength in 50 adults on hemodialysis using a handheld device. The goal is to create reference values for lower-limb strength in this group. Researchers will also check how strength relates to handgrip, walking speed, and quality of life.
Sponsor: Cardenal Herrera University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Emergency UTI treatment under review: study aims to cut unnecessary antibiotic use
Knowledge-focused Recruiting nowThis study looks at how doctors can improve antibiotic prescriptions for urinary tract infections (UTIs) after patients leave the emergency department. Researchers will check if adjusting antibiotics based on lab test results reduces the use of strong drugs like fluoroquinolones.…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Dialysis before surgery: does timing matter? new study aims to find out
Knowledge-focused Recruiting nowThis pilot study looks at whether giving dialysis on the same day as surgery is better than not giving it for people with end-stage kidney disease. About 30 participants will be randomly assigned to one of two schedules. Researchers will track safety issues like electrolyte probl…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Personalized trial matching could revolutionize kidney disease treatment
Knowledge-focused Recruiting nowThis study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…
Phase: NA • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New pill CTX001 aims to fix iron issues – first human tests begin
Knowledge-focused Recruiting nowThis early-stage trial tests a new drug called CTX001 in 72 healthy adults. The goal is to check for side effects and see how the drug affects iron levels in the blood, with or without iron supplements and food. It is a first step toward possibly treating anemia and iron deficien…
Phase: EARLY_PHASE1 • Sponsor: Cajal Therapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
54,000 patients to reveal the safest oxygen level during surgery
Knowledge-focused Recruiting nowThis study will look at 54,000 adults having surgery with general anesthesia to see how different oxygen levels affect their recovery. Patients will receive lower, intermediate, or higher oxygen during their operation. The goal is to find which oxygen level reduces the risk of or…
Phase: NA • Sponsor: Frederic T Billings IV • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could end painful bone biopsies for kidney disease patients
Knowledge-focused Recruiting nowThis study is testing whether a blood test that looks at tiny genetic molecules called microRNAs can accurately detect bone problems in people with chronic kidney disease. Currently, doctors rely on a bone biopsy, which is invasive and not practical for most patients. The researc…
Sponsor: Thomas Nickolas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can we predict hidden polyps in kidney stone patients?
Knowledge-focused Recruiting nowThis study is looking for factors that might predict inflammatory polyps in the ureter (the tube from kidney to bladder) in people with kidney stones. Researchers will review past patient data and then test their predictions on new patients. The goal is to create a simple tool th…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Kidney safety of painkillers in kids with CKD under the microscope
Knowledge-focused Recruiting nowThis study looks at whether short-term use of NSAID pain relievers (like ibuprofen) after surgery increases the risk of acute kidney injury in children with mild-to-moderate chronic kidney disease. About 164 children over 18 months old with CKD stages 2-3a who are having urologic…
Phase: PHASE4 • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New MRI study aims to improve kidney donor selection
Knowledge-focused Recruiting nowThis study uses special MRI scans to look at how well a donated kidney works in the recipient and how the donor's remaining kidney adapts over one year. It includes 80 adults (donors and recipients) and aims to help doctors choose the best kidneys for transplant. The goal is to b…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New monitoring methods could protect kidneys during surgery
Knowledge-focused Recruiting nowThis study watches how blood flows to the kidneys in 51 adults having elective minimally invasive abdominal surgery. Researchers use two non-invasive tools—ultrasound and light sensors—to measure kidney function at key times during and after surgery. The goal is to see if these t…
Sponsor: Istanbul University - Cerrahpasa • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Red meat swap may cut toxins in kidney patients
Knowledge-focused Recruiting nowThis study looks at whether replacing red meat with plant-based protein can lower levels of certain gut toxins in people with stage 3 chronic kidney disease. Fifteen participants will try both a vegetarian diet and a diet with red meat, with a break in between. Researchers will m…
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
TAVI study aims to uncover kidney risks from contrast dye
Knowledge-focused Recruiting nowThis study observes 1000 people with severe aortic stenosis and kidney disease who are getting a TAVI procedure. Researchers want to see how removing the blocked valve affects the kidneys' response to contrast dye used during the procedure. The goal is to understand if TAVI lower…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New kidney drug candidate SK-09 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study is testing a new oral drug called SK-09 in 72 healthy adults to see if it is safe and how the body processes it. The study is split into two parts: one where participants get a single dose, and another where they get multiple doses. No one knows who gets th…
Phase: PHASE1 • Sponsor: Consun Pharmaceutical Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC